Ruggero Galici is a Senior Director of Nonclinical and Clinical Pharmacology Medical Writing and heads global early-stage regulatory writing activities at Alexion Pharmaceuticals Inc, AstraZeneca Rare Disease Unit. In this role, he facilitates the transition of early-stage programs from research to clinical trial applications and investigational new drug submissions.

Ruggero has a background in drug discovery, nonclinical and clinical development, a PhD, and post-doctoral training in pharmacology. He has led pharmacology teams to advance small molecules and biologics to the clinic and has served as subject- matter expert to compound development teams. Ruggero has more than 20 years of experience in scientific and regulatory writing. He can be found on LinkedIn at https://www.linkedin.com/in/rgalici.